Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price

Executive Summary

Amgen said when Aimovig was approved that its $6,900 list price was designed to make sure a lot of patients could access the migraine prophylaxis. ICER now says that's a reasonable price, assuming a $5,000 net cost for the CGRP inhibitor, but only for patients who have failed on other treatments.

Advertisement

Related Content

Novartis Gets NICE Headache From Aimovig Knockback
Amgen's Aimovig Riding High With Strong Prescriber, Payer Acceptance
Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?
ICER’s 2019 Agenda Includes CAR-T Therapy, Drugs For Depression, Arthritis, AMD
Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most
Teva Pushes CGRP Timeline Back To End Of 2018
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel